U.S. health officials are reevaluating a $590 million contract that was awarded to Moderna for the development of its bird flu vaccine, Bloomberg News reported on Wednesday, citing sources.

Moderna is one of the pharmaceutical companies best known for developing the messenger RNA vaccine against Covid-19.

The Trump administration is reviewing a contract extended to Moderna in the final days of the Biden administration.

The Trump administration has not staffed an office established by Congress to prepare the nation for future pandemics, ...

The CDC has sequenced bird flu viruses from people in Nevada and Wyoming, and the Trump Administration has released a ...

Moderna’s mRNA-based bird flu vaccine mRNA-1018 is undergoing a Phase 1/2 study targeting H5 and H7 avian influenza viruses. In January 2025, the US Department of Health and Human Services (HHS ...

Arcturus Therapeutics believes it’s “highly unlikely” it will lose the promised government funding for its bird flu mRNA ...

Sky-high egg prices have drawn renewed attention to the bird flu outbreak, which has caused more than 166 million wild and ...

Under RFK Jr., HHS has canceled key vaccine meetings. Here's what that means for seasonal flu, bird flu, and childhood ...

Shares of the American pharmaceutical company Moderna (MRNA) climbed over 8% in pre-market trading following strategic ...